Literature DB >> 18520757

A critical overview of the evidence base for the contemporary surgical management of stress incontinence.

Yvonne Katherine P Koch1, Philippe Zimmern.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to evaluate the evidence base for surgical management of stress urinary incontinence in women between July 2006 and December 2007. RECENT
FINDINGS: The Urinary Incontinence Treatment Network and Pelvic Floor Diseases Network have contributed level 1 evidence in the management of stress urinary incontinence with multicentric randomized controlled trials. Pubovaginal sling has a higher success rate than the Burch at the expense of a higher morbidity. A prophylactic Burch procedure at the time of an abdominal sacrocolpopexy can reduce secondary stress urinary incontinence and urge urinary incontinence. Suburethral tapes have a higher cure rate for patients with predominant stress urinary incontinence and can safely be placed at the time of concomitant pelvic surgery. The tension-free vaginal tape has a higher rate of lower urinary tract injury and voiding dysfunction when compared with transobturator tape.
SUMMARY: The Burch and pubovaginal sling have a high success rate for treating stress urinary incontinence. Prospective randomized trials are needed to assess the long-term results of suburethral slings. There is still no consensus on outcome measures when reporting on surgical management for stress urinary incontinence.

Entities:  

Mesh:

Year:  2008        PMID: 18520757     DOI: 10.1097/MOU.0b013e3282fdf8d5

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  2 in total

1.  Ureteral erosion of a transvaginal tape.

Authors:  Homan Miraliakbari; Edward Tse
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

2.  Goal achievement as a patient-generated outcome measure for stress urinary incontinence.

Authors:  Jill L Milne; Magali Robert; Selphee Tang; Neil Drummond; Sue Ross
Journal:  Health Expect       Date:  2009-09       Impact factor: 3.377

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.